Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
MDGL
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-5.34
vs -4.75
Q4.23
N/A
-5.68
vs -4.98
Q1.24
N/A
-7.38
vs -4.23
Q2.24
N/A
-7.10
vs -4.69
Q3.24
N/A
-4.92
vs -5.34
Q4.24
N/A
-2.71
vs -5.68
Q1.25
N/A
-3.32
vs -7.38
Q2.25
N/A
-1.90
vs -7.10
Q3.25
N/A
-2.08
vs -4.92
Q4.25
N/A
-2.21
vs -2.71
Sales Growth
YoY
Current
Estimates
Q3.23
NA
NA vs NA
Q4.23
NA
770K vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
14.6M vs NA
Q3.24
NA
62.2M vs NA
Q4.24
+13318%
103.3M vs 770K
Q1.25
NA
137.3M vs NA
Q2.25
+1354%
212.8M vs 14.6M
Q3.25
+291%
242.9M vs 62.2M
Q4.25
+169%
277.5M vs 103.3M
Return on Equity
QoQ
Q1.23
-52%
-0.52
vs -0.44
Q2.23
-83%
-0.83
vs -0.52
Q3.23
-444%
-4.44
vs -0.83
Q4.23
-28%
-0.28
vs -4.44
Q1.24
-17%
-0.17
vs -0.28
Q2.24
-18%
-0.18
vs -0.17
Q3.24
-14%
-0.14
vs -0.18
Q4.24
-8%
-0.08
vs -0.14
Q1.25
-10%
-0.10
vs -0.08
Q2.25
-6%
-0.06
vs -0.10
Institutionnal Ownership
QoQ
Q1.23
248
248
vs 218
14%
Q2.23
238
238
vs 248
-4%
Q3.23
232
232
vs 238
-3%
Q4.23
257
257
vs 232
11%
Q1.24
312
312
vs 257
21%
Q2.24
288
288
vs 312
-8%
Q3.24
285
285
vs 288
-1%
Q4.24
321
321
vs 285
13%
Q1.25
341
341
vs 321
6%
Q2.25
325
325
vs 341
-5%
globenewswire.com
8 hours ago
zacks.com
9 hours ago
seekingalpha.com
16 hours ago
seekingalpha.com
17 hours ago
youtube.com
18 hours ago
Quote Panel
Key Metrics
Forecast
554%2026-Revenue
333%2026-EPS
2261%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
Cantor Fitzgerald
initialisePrevious: Not converted
2024-06-28
Now: Neutral
Wolfe Research
initialisePrevious: Not converted
2024-06-10
Now: Outperform
Bank of America Securities
initialisePrevious: Not converted
2024-04-22
Now: Underperform
Raymond James
upgradePrevious: Not converted
2022-12-19
Now: Market Perform
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-11.88Â ( -3.04%)
Relative Strenght
86
Volume Buzz
37%
Earning Acce
No
Dist 52w H.
4%Relative Strength
MDGL
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|